ORY-1001
- Generic Name
- ORY-1001
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C16H24N2
- CAS Number
- 1401966-39-9
- Unique Ingredient Identifier
- XC0UT08SNJ
- Associated Conditions
- -
- Associated Therapies
- -
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
- Conditions
- Interventions
- First Posted Date
- 2024-10-28
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 56
- Registration Number
- NCT06661915
Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML
- Conditions
- Interventions
- First Posted Date
- 2024-07-23
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 45
- Registration Number
- NCT06514261
- Locations
- 🇺🇸
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
🇺🇸UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 24
- Registration Number
- NCT06357182
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-03-01
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 45
- Registration Number
- NCT06287775
- Locations
- 🇺🇸
JHU Sidney Kimmel Comprehensive Cancer Center LAO, Baltimore, Maryland, United States
Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)
- Conditions
- Interventions
- First Posted Date
- 2022-09-21
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Oryzon Genomics S.A.
- Target Recruit Count
- 50
- Registration Number
- NCT05546580
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸Miami Cancer Institute, Miami, Florida, United States
Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET
- Conditions
- Interventions
- First Posted Date
- 2022-06-15
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 42
- Registration Number
- NCT05420636
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Huntsman Cancer Institute, Salt Lake City, Utah, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.